April 10, 2018 / 11:47 AM / 8 months ago

BRIEF-Helix Biopharma Corp. Announces Regulatory Approval To Dose Patients In A Phase II Randomized Study of L-DOS47 With Vinorelbine And Cisplatin

April 10 (Reuters) - Helix Biopharma Corp:

* HELIX BIOPHARMA CORP. ANNOUNCES REGULATORY APPROVAL TO DOSE PATIENTS IN A PHASE II RANDOMIZED STUDY OF L-DOS47 WITH VINORELBINE AND CISPLATIN

* ALL NECESSARY REGULATORY AND ETHICS APPROVALS HAVE BEEN RECEIVED TO DOSE FIRST PATIENT IN ITS LDOS003 TRIAL IN UKRAINE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below